Molecular mechanisms involved in cisplatin cytotoxicity

Cell Mol Life Sci. 2000 Aug;57(8-9):1229-35. doi: 10.1007/pl00000762.


cis-diamminedichloroplatinum(II) or cisplatin is a DNA-damaging agent that is widely used in cancer chemotherapy. Cisplatin cross-links to DNA, forming intra- and interstrand adducts, which bend and unwind the duplex and attract high-mobility-group domain and other proteins. Presumably due to a shielding effect caused by these proteins, the cisplatin-modified DNA is poorly repaired. The resulting DNA damage triggers cell-cycle arrest and apoptosis. Although it is still debatable whether the clinical success of cisplatin relies primarily on its ability to trigger apoptosis, at least two distinct pathways have been proposed to contribute to cisplatin-induced apoptosis in vitro. One involves the tumour-suppressor protein p53, the other is mediated by the p53-related protein p73. Coupling cisplatin damage to apoptosis requires mismatch repair activity, and recent observations further suggest involvement of the homologous recombinatorial repair system. At present it is generally accepted that abortive attempts to repair the DNA lesions play a key role in the cytotoxicity of the drug, and loss of the mismatch repair activity is known to cause cisplatin resistance, a major problem in antineoplastic therapy. Clearly, a better understanding of the signalling networks involved in cisplatin toxicity should provide a rational basis for the development of new therapeutic strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / toxicity
  • Cell Cycle / drug effects
  • Cell Survival / drug effects
  • Cisplatin / toxicity*
  • Cross-Linking Reagents / toxicity
  • DNA / drug effects*
  • DNA Adducts*
  • DNA Damage
  • DNA Repair
  • Humans


  • Antineoplastic Agents
  • Cross-Linking Reagents
  • DNA Adducts
  • DNA
  • Cisplatin